Apogee Therapeutics Dividends and Buybacks

Dividend criteria checks 0/6

Apogee Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-18.1%

Buyback Yield

Total Shareholder Yield	-18.1%
Future Dividend Yield	0%
Dividend Growth	n/a
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Payout ratio	n/a

Recent dividend and buyback updates

No updates

Recent updates

We're Interested To See How Apogee Therapeutics (NASDAQ:APGE) Uses Its Cash Hoard To Grow

Mar 05

Apogee Therapeutics' Innovative Leap In Atopic Dermatitis Management

Mar 05

We're Not Worried About Apogee Therapeutics' (NASDAQ:APGE) Cash Burn

Nov 21

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if APGE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if APGE's dividend payments have been increasing.

Dividend Yield vs Market

Apogee Therapeutics Dividend Yield vs Market

How does APGE dividend yield compare to the market?
Segment	Dividend Yield
Company (APGE)	n/a
Market Bottom 25% (US)	1.3%
Market Top 25% (US)	4.2%
Industry Average (Biotechs)	2.3%
Analyst forecast (APGE) (up to 3 years)	0%

Notable Dividend: Unable to evaluate APGE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate APGE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate APGE's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as APGE has not reported any payouts.

Apogee Therapeutics Dividends and Buybacks

Dividend criteria checks 0/6

Key information

Recent dividend and buyback updates

Recent updates

We're Not Very Worried About Apogee Therapeutics' (NASDAQ:APGE) Cash Burn Rate

Apogee Therapeutics Earnings Preview: APG777's Potential In Atopic Dermatitis

Apogee Therapeutics, Inc. Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for Treatment for Atopic Dermatitis and Other Inflammatory Diseases

Apogee Therapeutics, Inc. Appoints Jeff S. Hartness as Chief Commercial Officer

Apogee Therapeutics, Inc. Announces First Participants Dosed in Phase 1 Clinical Trial of APG990 its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

Apogee Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

We're Not Very Worried About Apogee Therapeutics' (NASDAQ:APGE) Cash Burn Rate

Apogee Therapeutics: Infrequent Dosing Advantage In Biotech Play

Apogee Therapeutics, Inc. Appoints Lisa Bollinger to Its Board of Directors

Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

Apogee Therapeutics, Inc., Annual General Meeting, Jun 05, 2024

Apogee Therapeutics, Inc., Annual General Meeting, Jun 05, 2024

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases

Apogee Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $419.999966 million.

Apogee Therapeutics, Inc. has filed a Follow-on Equity Offering.

We're Interested To See How Apogee Therapeutics (NASDAQ:APGE) Uses Its Cash Hoard To Grow

Apogee Therapeutics' Innovative Leap In Atopic Dermatitis Management

Apogee Therapeutics, Inc. Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases

We're Not Worried About Apogee Therapeutics' (NASDAQ:APGE) Cash Burn

New minor risk - Share price stability

Apogee Therapeutics, Inc. and Paragon Therapeutics, Inc. Announce Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology (EADV) Congress

Apogee Therapeutics, Inc. Appoints Mark C. Mckenna as Chairman of Its Board of Directors

Apogee Therapeutics, Inc. has completed an IPO in the amount of $300.05 million.

Apogee Therapeutics, Inc. has completed an IPO in the amount of $300.05 million.

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies